# OrphanCure Full Pipeline Report: repodb_0d57eaf7fcf55450

- Drug: Valproic Acid
- Disease: Absence Epilepsy
- Mode: no_graph_features
- Status: completed
- Final assessment: Potential

This generated report is for research support only and is not medical advice.

## Structured Output

```json
{
  "sections": {
    "1_executive_summary": {
      "conclusion": "Potential",
      "confidence": "Medium",
      "summary": "Valproic acid (VPA) is recognized as a highly effective medication for juvenile myoclonic epilepsy (JME). While its efficacy is established, concerns regarding teratogenic potential and adverse drug effects have led to its withdrawal in some cases, prompting the use of alternative treatments like levetiracetam and lamotrigine. However, VPA remains a benchmark for treatment success in JME.",
      "evidence_counts": {
        "total_papers": 45,
        "supporting": 16,
        "contradicting": 9,
        "inconclusive": 20
      },
      "common_targets_count": 0
    },
    "2_normalized_hypothesis": {
      "statement": "Repurpose VALPROIC ACID for myoclonic epilepsy",
      "drug": {
        "id": "CHEMBL109",
        "name": "VALPROIC ACID",
        "aliases": [
          "Valproate",
          "Depakene",
          "Depakote",
          "VPA",
          "Epilim"
        ],
        "resolution_method": "auto"
      },
      "disease": {
        "id": "EFO_1001900",
        "name": "myoclonic epilepsy",
        "aliases": [
          "myoclonic-atonic epilepsy",
          "epilepsy, myoclonic",
          "myoclonic seizures with epilepsy",
          "epilepsia myoclonica",
          "myoclonic epilepsy syndrome"
        ],
        "resolution_method": "auto"
      }
    },
    "3_mechanistic_rationale": {
      "total_mechanisms": 0,
      "mechanisms": []
    },
    "4_target_overlap_summary": {
      "total_overlapping": 0,
      "top_targets": []
    },
    "5_literature_evidence_summary": {
      "total_retrieved": 45,
      "polarity": {
        "supports": 16,
        "contradicts": 9,
        "inconclusive": 20
      },
      "support_ratio": "16 of 45 retrieved papers support the hypothesis",
      "queries_used": 10,
      "top_papers": [
        {
          "pmid": "33423017",
          "title": "Response to levetiracetam or lamotrigine in subjects with Juvenile Myoclonic Epilepsy previously treated with valproic acid: A single center retrospective study.",
          "year": "2021",
          "relevance_score": 9.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Case report limit",
            "Title Match"
          ]
        },
        {
          "pmid": "34817852",
          "title": "Topiramate for juvenile myoclonic epilepsy.",
          "year": "2021",
          "relevance_score": 8.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "37267668",
          "title": "Diagnosis and treatment of late-onset myoclonic epilepsy in Down syndrome (LOMEDS): A systematic review with individual patients' data analysis.",
          "year": "2023",
          "relevance_score": 7.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "38117708",
          "title": "[Reflex triggers in juvenile myoclonic epilepsy].",
          "year": "2023",
          "relevance_score": 7.0,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "37378757",
          "title": "Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.",
          "year": "2023",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study",
            "Recent"
          ]
        },
        {
          "pmid": "30687937",
          "title": "Topiramate for juvenile myoclonic epilepsy.",
          "year": "2019",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "28434203",
          "title": "Topiramate monotherapy for juvenile myoclonic epilepsy.",
          "year": "2017",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "38461125",
          "title": "Drug-resistant juvenile myoclonic epilepsy: A literature review.",
          "year": "2024",
          "relevance_score": 7.0,
          "polarity": "INCONCLUSIVE",
          "match_reasons": [
            "Recent"
          ]
        },
        {
          "pmid": "26695884",
          "title": "Topiramate monotherapy for juvenile myoclonic epilepsy.",
          "year": "2015",
          "relevance_score": 7.0,
          "polarity": "CONTRADICTS",
          "match_reasons": [
            "Contradiction signal",
            "Clinical study"
          ]
        },
        {
          "pmid": "39720197",
          "title": "The Use of Perampanel in the Treatment of Lance-Adams Syndrome.",
          "year": "2024",
          "relevance_score": 6.5,
          "polarity": "SUPPORTS",
          "match_reasons": [
            "Case report limit",
            "Recent"
          ]
        }
      ]
    },
    "6_contradictory_evidence": {
      "count": 1,
      "claims": [
        {
          "claim_id": "CTR-2f339e",
          "statement": "Valproic acid is often withdrawn due to teratogenic potential or adverse drug effects, leading to the use of alternative medications.",
          "evidence_count": 2
        }
      ]
    },
    "7_confidence_assessment": {
      "overall": "Medium",
      "dimensions": {
        "mechanistic_strength": "Low",
        "literature_strength": "Medium",
        "clinical_evidence": "High"
      },
      "quality_scorecard": {
        "overall_score": 0.85,
        "decision": "finalize",
        "dimensions": {
          "completeness": {
            "score": 1.0,
            "reason": "5/5 sections present"
          },
          "evidence_support": {
            "score": 1.0,
            "reason": "2/2 claims have paper evidence"
          },
          "citation_validity": {
            "score": 1.0,
            "reason": "2 verified, 0 partial out of 2"
          },
          "mechanistic_specificity": {
            "score": 0.0,
            "reason": "0/2 claims reference targets"
          },
          "contradiction_handling": {
            "score": 0.8,
            "reason": "Contradictory evidence discussed"
          },
          "traceability": {
            "score": 1.0,
            "reason": "2/2 claims have provenance"
          },
          "output_structure": {
            "score": 1.0,
            "reason": "Executive summary + confidence assessment"
          },
          "actionability": {
            "score": 1.0,
            "reason": "3 next steps, 3 data gaps identified"
          }
        },
        "weak_dimensions": [
          "mechanistic_specificity"
        ],
        "rerun_targets": []
      }
    },
    "8_risk_flags_limitations": {
      "risk_flags": [
        "Adverse drug effects associated with Valproic Acid.",
        "Teratogenic potential of Valproic Acid."
      ],
      "limitations": [
        "The provided literature primarily focuses on the comparison of VPA with other drugs or discusses alternative treatments, rather than providing novel mechanistic insights for VPA repurposing.",
        "The evidence for VPA's efficacy in JME is strong, but its use is limited by safety concerns, particularly teratogenicity."
      ],
      "missing_data": [
        "Detailed mechanistic data for Valproic Acid in Myoclonic Epilepsy.",
        "Specific data on the incidence and severity of adverse drug effects of Valproic Acid in JME.",
        "Comparative studies on VPA versus newer AEDs in terms of seizure freedom and tolerability in JME."
      ]
    },
    "9_recommended_next_steps": {
      "clinical_next_steps": [
        "Investigate alternative medications for JME in women of childbearing age due to VPA's teratogenic potential.",
        "Evaluate the specific adverse drug effects that lead to VPA withdrawal in JME patients.",
        "Compare the long-term efficacy and tolerability of VPA with newer AEDs in specific JME patient subgroups."
      ]
    },
    "10_claim_evidence_table": {
      "total_claims": 2,
      "claims": [
        {
          "claim_id": "CLM-1edae2",
          "statement": "Valproic acid is an effective medication for juvenile myoclonic epilepsy.",
          "confidence_numeric": 0.9,
          "confidence_label": "HIGH",
          "polarity": "INCONCLUSIVE",
          "verification_status": "VERIFIED",
          "targets": [],
          "citation_count": 2,
          "risk_flags": []
        },
        {
          "claim_id": "CTR-2f339e",
          "statement": "Valproic acid is often withdrawn due to teratogenic potential or adverse drug effects, leading to the use of alternative medications.",
          "confidence_numeric": 0.5,
          "confidence_label": "MEDIUM",
          "polarity": "CONTRADICTS",
          "verification_status": "VERIFIED",
          "targets": [],
          "citation_count": 2,
          "risk_flags": []
        }
      ]
    },
    "11_provenance_appendix": {
      "total_entries": 2,
      "entries": [
        {
          "claim_id": "CLM-1edae2",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "36aab810f2ac",
          "timestamp": "2026-06-03T12:24:03.124526+00:00",
          "paper_evidence": [
            {
              "pmid": "33423017",
              "snippet": "Valproic acid (VPA) is the most effective medication in juvenile myoclonic epilepsy (JME) but, due to its teratogenic potential, levetiracetam (LEV) and lamotrigine (LTG) are preferred in women of chi",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "33423017",
              "snippet": "We retrospectively analyzed 65 patients with JME which had been followedup at the Epilepsy Center of Pisa University Hospital, identifying 28 subjects who had been successfully treated with VPA monoth",
              "polarity": "SUPPORTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 10
        },
        {
          "claim_id": "CTR-2f339e",
          "source_agent": "SynthesisCriticAgent",
          "source_run": "36aab810f2ac",
          "timestamp": "2026-06-03T12:24:03.124526+00:00",
          "paper_evidence": [
            {
              "pmid": "33423017",
              "snippet": "Valproic acid (VPA) is the most effective medication in juvenile myoclonic epilepsy (JME) but, due to its teratogenic potential, levetiracetam (LEV) and lamotrigine (LTG) are preferred in women of chi",
              "polarity": "CONTRADICTS",
              "verification": "VERIFIED",
              "error": null
            },
            {
              "pmid": "33423017",
              "snippet": "The aim of this study was to compare the effectiveness and tolerability of LEV and LTG monotherapy in patients with a previous good seizure control in VPA monotherapy, in which VPA was withdrawn becau",
              "polarity": "CONTRADICTS",
              "verification": "VERIFIED",
              "error": null
            }
          ],
          "mechanism_evidence": [],
          "queries_used_count": 0
        }
      ]
    }
  },
  "metadata": {
    "run_id": "36aab810f2ac",
    "created_at": "2026-06-03T12:23:43.772555+00:00",
    "drug": "VALPROIC ACID",
    "disease": "myoclonic epilepsy",
    "total_claims": 2,
    "quality_score": 0.85,
    "reruns": 0
  }
}
```
